Market Place
Sourcing Support
Four Independent Studies Show Rovalpituzumab Tesirine Ineffective Against SCLC
07 Sep 2021 //
SCIENCEDAILY
AbbVie shuts Rova-T development in first-line advanced small-cell lung cancer
31 Aug 2019 //
PHARMAFILE
AbbVie Cuts 178 Stemcentrx Employees Months After Rova-T Failure
29 Mar 2019 //
BIOSPACE
Abbvie to record $4 billion impairment charges on Stemcentrx assets
05 Jan 2019 //
REUTERS
Mega-blockbuster valuation AbbVie assigned to Rova-T starting to vanish, quietly
04 Jan 2019 //
ENDPTS
AbbVie dishes out $105M for CD39 pact with Tizona’s new CEO from Roche
03 Jan 2019 //
ENDPTS
#ASCO18: AbbVie convinces one top analyst that Rova-T is worthless
06 Jun 2018 //
ENDPTS
AbbVie’s Upadacitinib Looks Good in RATrial; Rova-T Looks Worse in Lung Ca
05 Jun 2018 //
BIOSPACE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.